Taken together, these data suggested the potential utility of treatment targeting microenvironmental VEGFR2 signaling with the blockade of FOXM1 for a better survival outcome in patients diagnosed with advanced-stage AFP-positive HCC. This evidence concerns the gene FOXM1 and hepatocellular carcinoma.